Mission
We are passionate to deliver first in class cancer drugs to patients.
2030 Vision
To be an R&D oriented pharmaceutical company based in Japan.
Message
We are passionate to deliver first in class cancer drugs to patients from Japan.
Chordia Therapeutics is a biotech company engaged in research and development of novel therapies for cancers.
Professionals who have deep knowledge and experience for oncology area keep on striving toward developing new drugs that will envision the tomorrow of cancer treatment.
In general, it takes a long time for bringing out a new drug to patients.
And we also need the cooperation from collaborators and supporters.
So, the thing that our company always cares about is the speedy research and development which is derived from quick decision-making as an R&D oriented biotech, and the gratitude to our external partners who support our company.
We are advancing drug development quickly and steadily by making the best use of the flexibility of lean organization, broad network of experienced professionals, and the accumulated R&D wisdom.
Out lead asset CLK inhibitor CTX-712, currently under first-stage of clinical trials, has a novel mode of action that kills cancer cells by altering mRNA splicing.
The key to the sustainable growth of biotech companies is the successful development of new drugs, and we aspire to deliver the first in class anti-cancer drug from Japan to patients around the world as soon as possible by leveraging our strengths.
CEO Hiroshi Miyake
Joined Takeda Pharmaceutical Company Limited in 1998 after graduating from the Faculty of Pharmaceutical Sciences, Osaka University and Ph.D. in Pharmacology from University of Tokyo. He is involved in HIV virus research and drug discovery in the oncology area. In November 2017, he started his business from Takeda Pharmaceutical Company Limited, launched Chordia Therapeutics and became CEO.
Leadership Team
CEO
Hiroshi Miyake
CSO
Daisuke Morishita
CFO
Kentaro Kume
CEO Hiroshi Miyake
Hiroshi Miyake, Ph.D.is a co-founder of Chordia Therapeutics and he has served as President and CEO and act as a member of the board of directors since Chordia’s incorporation in November 2017. He has over 20 years experiences in drug discovery and his team delivered a program to clinical stage six times. Before the foundation of Chordia, he served as the site head of oncology drug discovery unit at Takeda Pharmaceuticals. He earned his B.S. from Osaka university and Ph.D. in Pharmacology from University of Tokyo.
CSO Daisuke Morishita
DAISUKE MORISHITA (Ph.D.) is the Chief Scientific Officer at Chordia Therapeutics and leads research initiatives developing cancer treatments that change lives. Prior to founding Chordia in November 2017, DAISUKE invested ten years working on oncology therapeutics at TAKEDA pharmaceutical company, focusing on cancer-related RNA networks. As the industry-academia collaboration representative at TAKEDA, DAISUKE led the CTX-177 drug discovery research. Through the success of the CTX-177 research program, DAISUKE was invited and currently holds an associate professorship at Kyoto University to pursue research into therapeutic strategies in cancer-related RNA networks and adjunct professorships at Kumamoto University and Nagoya City University to produce next-generation anti-cancer drugs. DAISUKE received a Ph.D. in oncology from the University of Tokyo.
CMO Kunihiko Takeyama
Kunihiko Takeyama, MD, PhD has served as chief medical officer at Chordia since 2019. Prior to joining Chordia, Kuni was professor at Center for Clinical Research Administration & Innovation at Tokyo Medical University, Tokyo. Prior to Tokyo Medical University, Kuni spent several years at Takeda, where he was vice president and head of the oncology therapeutic area unit for Japan and Asea. Before Takeda, Kuni was head of Japan oncology R&D and oncology medical lead of Japan/Pacific region at Sanofi, Tokyo; head of clinical science department of R&D at BMS, Tokyo. Before joining pharmaceutical industry, Kuni was instructor of medicine at Harvard Medical School, and had translational research work at Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, where he was director of lymphoma target testing center. Earlier in his research work, Kuni was at Beth Israel Deaconess Medical Center, Boston. In his clinical careers, Kuni had significant clinical work activities at several major hospitals including National Cancer Center Hospital, Tokyo as head of leukemia/transplant division. Kuni received MD and PhD from Nagoya University School/Graduate School of Medicine, Japan. Kuni is board certified hematologist and internist, and currently serves as adjunct professor at Center for Clinical Research Administration & Innovation, and Department of Hematology at Tokyo Medical University, where he provides services of hematology-oncology and cancer survivor clinic. Kuni also serves as adjunct professor at Tokyo University of Pharmacy and Life Science.
CFO Kentaro Kume
Kentaro Kume brings over 20 years of experience with a multi-disciplinary background in corporate finance, M&A, Procurement, Transformatoin, and business strategy with Japan Financial Corporation, Cabinet office, Kearney and Takeda Pharmaceutical. Most recently, Kentaro served establishment and management of Spinout companies to realize Eco-system in iPark as a Head of Strategy & Operation APAC Center for External Innovation for Takeda Pharmaceutical. He received a Bachelor of Economic degree from Kyoto University and a Master of Management Technology degree from Tokyo University of Science.</p<
CBO Masami Yuhara
Board of Directors
Hiroshi Miyake
Representative Director
Akihiko Shimauchi
External Director
Kosuke Ishii
External Director, Audit and Supervisory Committee member
CPA
Ayuko Hashimoto
External Director, Audit and Supervisory Committee member
Attorney
Yukari Nishikata
External Director, Audit and Supervisory Committee member
Business Model
Lead and accelerate a life science eco-system and various players (e.g. Academia, Pharma Company, Investor, Government, CRO (Contract Research Organization and so on) to realize drug discovery process.
Chordia is focusing on Research and Development of anti-cancer drug from target discovery to Proof of Concept (POC). Chordia is also flexible organization structure for maximizing value of patient and company by corresponding to strategic partner’s proposals.
Brand Origin
Corporate Name
Chordia is derived from the word ‘chord’, which are musical notes that sound pleasant when played together.
Like a chord, we are working towards harmonizing our energy and passion for science with our collaborators, supporters, and stakeholders to enable the discovery of innovative drugs.
Corporate Colors
Our corporate colors are Navy Peony as a main color, and Greenery as a sub color selected from PANTONE Color. Navy Peony is a dependable and an anchoring shade, and Greenery is a refreshing and revitalizing one.
Greenery is Pantone Colour of the Year 2017, which is also Chordia’s start-up year.
Logomark is designed by Nonoka Imai
Corporate Symbol
Our corporate symbol is derived from leaf and fruit of China root (Smilax china), and symbolizes our never-give-up attitude which is its floriography.
Furthermore, two leaves and three berries delineate our cudding figure with patient, and drugs to be delivered to patients, respectively.
Company Profile
- Corporate Name
- Chordia Therapeutics Inc.
- Foundation
- November 1, 2017
- Head Office
- 26-1, Muraoka-Higashi 2-chome, Fujisawa,Kanagawa, 251-0012 Japan
- Tokyo Office
- 3-11-5, Nihonbashi-honcho, Chuo-ku, Tokyo 103-0023 Japan
- Representative
- Hiroshi Miyake, Ph.D. CEO
Head Office
Tokyo Office
History
- October 2017
- Launch of Chordia Therapeutics
- November 2017
- Raises $~11 million in Series A Financing
- November 2018
- Initiate Phase 1 Study for CTX-712
- March 2019
- Raises $~27 million in Series B Financing
- December 2020
- Notice of license agreement with Ono Pharmaceutical
- May 2022
- Raises $~31 million in Series C Financing